[go: up one dir, main page]

MX2019015315A - Composiciones y tratamientos para el trastorno del sueño. - Google Patents

Composiciones y tratamientos para el trastorno del sueño.

Info

Publication number
MX2019015315A
MX2019015315A MX2019015315A MX2019015315A MX2019015315A MX 2019015315 A MX2019015315 A MX 2019015315A MX 2019015315 A MX2019015315 A MX 2019015315A MX 2019015315 A MX2019015315 A MX 2019015315A MX 2019015315 A MX2019015315 A MX 2019015315A
Authority
MX
Mexico
Prior art keywords
treatments
compositions
sleep disorder
pharmaceutical composition
relates
Prior art date
Application number
MX2019015315A
Other languages
English (en)
Other versions
MX387442B (es
Inventor
Karelis Harry
Gordon Mara
Smith Stewart
Washer Stewart
Washer Patrizia
Original Assignee
Zelda Therapeutics Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017902338A external-priority patent/AU2017902338A0/en
Application filed by Zelda Therapeutics Operations Pty Ltd filed Critical Zelda Therapeutics Operations Pty Ltd
Publication of MX2019015315A publication Critical patent/MX2019015315A/es
Publication of MX387442B publication Critical patent/MX387442B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Anesthesiology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La invención se refiere a una composición farmacéutica que comprende un extracto de Cannabis y opcionalmente uno o más portadores, diluyentes, adyuvantes, excipientes o cualquier combinación de los mismos farmacéuticamente aceptables, el extracto de Cannabis comprende una fracción de cannabinoides que comprende ?9-Tetrahidrocannabinol (THC), Cannabidiol (CBD) y Cannabinol (CBN) y una fracción de terpenos en una cantidad de al menos 3 % en peso del extracto. La invención también se refiere a métodos para tratar trastornos del sueño mediante el uso de esta composición farmacéutica.
MX2019015315A 2017-06-19 2018-06-19 Composiciones y tratamientos para el trastorno del sueño MX387442B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017902338A AU2017902338A0 (en) 2017-06-19 Sleep Disorder Composition and Treatment Thereof
AU2017904818A AU2017904818A0 (en) 2017-11-29 Sleep Disorder Compositions and Treatments Thereof
PCT/AU2018/050604 WO2018232448A1 (en) 2017-06-19 2018-06-19 COMPOSITION AGAINST SLEEP APNEA AND RELATED TREATMENTS

Publications (2)

Publication Number Publication Date
MX2019015315A true MX2019015315A (es) 2020-02-17
MX387442B MX387442B (es) 2025-03-18

Family

ID=62947713

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019015315A MX387442B (es) 2017-06-19 2018-06-19 Composiciones y tratamientos para el trastorno del sueño

Country Status (16)

Country Link
US (2) US20210145910A1 (es)
EP (1) EP3641754A4 (es)
JP (1) JP2020524151A (es)
KR (1) KR20200104278A (es)
CN (1) CN110944632A (es)
AU (2) AU2018100837B4 (es)
BR (1) BR112019026877A2 (es)
CA (1) CA3065563C (es)
CL (1) CL2019003635A1 (es)
CO (1) CO2019013887A2 (es)
IL (1) IL271503A (es)
MX (1) MX387442B (es)
NZ (1) NZ759963A (es)
PE (1) PE20201163A1 (es)
SG (1) SG11201912380XA (es)
WO (1) WO2018232448A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3031810A1 (en) 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
CA3089994A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
EP3864000A4 (en) 2018-10-10 2022-08-10 Treehouse Biosciences, Inc. CANNABIGEROL SYNTHESIS
CA3027876A1 (en) * 2018-12-18 2020-06-18 Tetra Bio-Pharma Cannabis compositions and methods
NL2022616B1 (en) * 2019-02-21 2020-09-18 Patrick Alexander Unger Cannabigerol and pharmaceutical compositions comprising cannabigerol for use in the treatment of insomnia
US10946054B1 (en) * 2019-10-08 2021-03-16 Jenny's Rose, LLC Therapeutic cannabis extracts
WO2021178579A1 (en) * 2020-03-03 2021-09-10 Alte Verde Llc Cannabis treatment of insomnia, pain, and skin conditions
CA3150874A1 (en) * 2020-03-09 2021-09-16 Anna PERSAUD Compositions comprising functional fragrances and cannabis-derived compounds
CN112057894A (zh) * 2020-09-08 2020-12-11 云南工麻生物科技有限公司 一种提取大麻二酚的方法
WO2022115921A1 (en) * 2020-12-04 2022-06-09 Cymra Life Sciences Limited Antiinflammatory compositions comprising cannabidiol, delta-9- tetrahydrocannabinol and linalool
CN113143995A (zh) * 2021-01-21 2021-07-23 龙麻(上海)医药研发有限责任公司 一种大麻提取物舌下片及其制备工艺和应用
CN112999218A (zh) * 2021-01-21 2021-06-22 龙麻(上海)医药研发有限责任公司 一种具有镇静助眠功效的组合物及用途
EP4284349A1 (en) * 2021-01-28 2023-12-06 Zynerba Pharmaceuticals, Inc. Treatment of sleep apnea with cbd
CN112791151B (zh) * 2021-02-20 2022-04-01 山东新稀宝股份有限公司 一种具有改善睡眠功能的组合物及应用
DK181329B1 (en) 2021-05-04 2023-08-16 Cs Medica As Nasal sleep spray composition, method for its provision, and receptacle and kit comprising said composition
US20220401407A1 (en) * 2021-06-09 2022-12-22 Demetrix, Inc. Regulation of the sleep/wake cycle using cannabinoid compounds
EP4469039A4 (en) * 2022-01-27 2026-01-07 Defined Res Inc CANNABIDIOL (CBD) AND TERPENE FORMULATION TO IMPROVE RESTFUL SLEEP IN MEN

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949582B1 (en) * 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
PL226646B1 (pl) 2002-08-14 2017-08-31 Gw Pharma Ltd Botaniczna substancja lekowa
GB2418612A (en) 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB201117956D0 (en) 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
DK2844243T3 (da) 2012-05-03 2020-02-03 Echo Pharmaceuticals Bv Fremgangsmåde til fremstilling af et cannabisplante-isolat omfattende delta-9-tetrahydrocannabinol
WO2014100231A1 (en) 2012-12-18 2014-06-26 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
EP3007714A1 (en) * 2013-06-13 2016-04-20 Cannabis Science International Holding BV Composition for the treatment of neurobehavioral disorders
CN103355391A (zh) * 2013-08-13 2013-10-23 汕头大学医学院第一附属医院 一种五味健脑益智饼及其制备方法
US10265292B2 (en) 2013-09-18 2019-04-23 The Werc Shop, LLC Terpene-based compositions, processes methodologies
CA3013907C (en) 2013-10-29 2020-09-08 Biotech Institute, Llc Production and use of specialty cannabis with bd/bt genotype and a limonene-dominant terpene profile
KR20160094950A (ko) 2013-10-31 2016-08-10 풀 스펙트럼 래버러토리즈, 리미티드 테르펜 및 칸나비노이드 제제
CN105010577A (zh) 2014-04-17 2015-11-04 天津市麦地那食品贸易有限公司 一种火麻、橄榄、葡萄籽、葵花籽调和油
EP3160445B1 (en) 2014-06-26 2021-10-20 Island Breeze Systems Ca, LLC Mdi related products and methods of use
AU2015308546A1 (en) 2014-08-25 2017-04-13 Clk Consult V/ Carsten Leonhard Knudsen Device with compositions for delivery to the lungs, the oral mucosa and the brain
AU2015335997B2 (en) * 2014-10-21 2020-10-01 United Cannabis Corp. Cannabis extracts and methods of preparing and using same
EA201791299A1 (ru) 2014-12-12 2017-12-29 ОХАЙ ЭНЕРДЖЕТИКС ПиБиСи Микроинкапсулированные композиции каннабиноидов
EP3250200A4 (en) * 2015-01-31 2018-09-19 Constance Therapeutics, Inc. Methods for preparation of cannabis oil extracts and compositions
AU2016225026A1 (en) 2015-02-27 2017-09-07 Canopy Growth Corporation Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
EP4193990A1 (en) * 2015-05-28 2023-06-14 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
IL246790A0 (en) * 2016-07-14 2016-09-29 Friedman Doron Self-dissolving compounds of cannabinoids
CA3031810A1 (en) * 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
MX386086B (es) 2016-08-03 2025-03-18 Zelda Therapeutics Operations Pty Ltd Composicion de cannabis
US9649349B1 (en) * 2017-01-19 2017-05-16 Metamorphic Alchemy & Distillations, Inc. System and method for producing a terpene-enhanced cannibinoid concentrate
EP3600284A4 (en) * 2017-03-20 2020-12-09 Kanabo Research Ltd. VAPORIZABLE COMPOSITIONS CONTAINING CANNABINOL
US20180352848A1 (en) * 2017-06-07 2018-12-13 NC3 Systems Smokable cannabis-based product with reduced psychoactive effects
CN111263638A (zh) 2017-09-15 2020-06-09 塞尔达治疗手术有限公司 用于治疗自闭症的组合物和方法
CA3089994A1 (en) * 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
AU2018100924A4 (en) 2018-07-03 2018-08-09 Zelira Therapeutics Operations Pty Ltd Composition and method for treating pain
JP2023529476A (ja) 2020-06-12 2023-07-10 ゼリラ セラピューティクス オペレーションズ ピーティーワイ リミテッド 慢性疼痛を治療するための組成物及び方法
CA3204196A1 (en) 2020-11-06 2022-05-12 Zelira Therapeutics Operations Pty Ltd Cannabinoid encapsulation technology

Also Published As

Publication number Publication date
EP3641754A4 (en) 2021-03-10
PE20201163A1 (es) 2020-10-28
US20210145910A1 (en) 2021-05-20
AU2018100837A4 (en) 2018-07-26
NZ759963A (en) 2022-07-01
KR20200104278A (ko) 2020-09-03
MX387442B (es) 2025-03-18
AU2018286647B2 (en) 2024-03-28
IL271503A (en) 2020-02-27
BR112019026877A2 (pt) 2020-06-30
WO2018232448A1 (en) 2018-12-27
AU2018100837B4 (en) 2019-02-21
CL2019003635A1 (es) 2020-06-19
US20230270808A1 (en) 2023-08-31
CA3065563C (en) 2023-06-13
CO2019013887A2 (es) 2020-04-01
CA3065563A1 (en) 2018-12-27
SG11201912380XA (en) 2020-01-30
CN110944632A (zh) 2020-03-31
EP3641754A1 (en) 2020-04-29
US12239680B2 (en) 2025-03-04
AU2018286647A1 (en) 2020-01-16
JP2020524151A (ja) 2020-08-13

Similar Documents

Publication Publication Date Title
MX2019015315A (es) Composiciones y tratamientos para el trastorno del sueño.
PE20230607A1 (es) Composicion de cannabis
PE20200726A1 (es) Composicion de cannabis
MX2021008702A (es) Uso de cannabinoides en el tratamiento de las comorbilidades asociadas a la epilepsia.
CL2020003368A1 (es) Composicion y metodo para tratar el dolor
MX2020007784A (es) Uso de cannabinoides en el tratamiento de la epilepsia.
CL2019000268A1 (es) Composición de cannabis.
CL2021002646A1 (es) Métodos y composiciones para su uso en el tratamiento del cáncer sin efectos psicosactivos
MX2020005719A (es) Uso de cannabinoides en el tratamiento de epilepsia.
MX2020003934A (es) Uso de cannabidiol en combinacion con agonistas del receptor 5-ht2b o anfetamina en el tratamiento de la epilepsia.
MX2021006094A (es) Uso de cannabinoides en el tratamiento de epilepsia.
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
CO2018013654A2 (es) Composiciones nasales de cannabidiol
MX2021006270A (es) Uso de cannabidiol en el tratamiento del complejo de esclerosis tuberosa.
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
CL2020003373A1 (es) Composición y método de ahorro de opiáceos
CL2022003507A1 (es) Composición y método para tratar el dolor crónico
MX2021010912A (es) Extractos bacterianos estables como farmacos.
MX2020004232A (es) Composiciones de cannabinoides y sus metodos de uso.
PE20211198A1 (es) Metodos y formulaciones para tratar nauseas y vomitos inducidos por quimioterapia
CO2021001059A2 (es) Composición de cannabinoides y método para tratar el ptsd y/o la ansiedad
MX2021003832A (es) Metodo y composicion para aliviar la fatiga y restaurar la energia.
BR112019002213A2 (pt) composições e o uso das mesmas para tratar ou prevenir rosácea
CO2021006279A2 (es) Métodos y tratamientos para la disfunción eréctil
CL2021001076A1 (es) Composición farmacéutica que comprende una combinación de 1,3-2,5% de tetrahidrocannabinol (thc) y 0,6-1,4% de cannabidiol (cbd); su proceso de elaboración; y su uso para el tratamiento del dolor crónico refractario.